GoKawiilNovartis licenses Abogen drug in deal worth up to $7.8 billion
Novartis has agreed to license a drug from Chinese biotech Abogen in a deal valued at up to $7.8 billion. Abogen describes its lead drug as having the potential to transform treatment for patients with autoimmune diseases.